Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.

中文翻译：

---

甘油三酯的临床评价

摘要 高甘油三酯血症是一种常见的临床问题。流行病学和遗传学研究已经证实，富含甘油三酯的脂蛋白 (TRL) 及其残留物是导致 ASCVD 的重要因素，而严重的高甘油三酯血症会增加患胰腺炎的风险。虽然低密度脂蛋白是降脂治疗的主要治疗目标，但目前的指南推荐反映 TRL 贡献的次要目标，如 apoB 和非 HDL-C。降低严重升高的甘油三酯对于避免或降低胰腺炎的风险很重要。在这里，我们讨论了高甘油三酯血症的干预措施，包括饮食和生活方式、已建立的治疗方法（例如贝特类和 omega-3 脂肪酸制剂）以及新兴疗法（包括各种生物制剂）。